Cimerli™ (ranibizumab-eqrn) was FDA approved on August 2, 2022 as interchangeable with Lucentis ® (ranibizumab). Cimerli is the third interchangeable biosimilar approved in the US, following Semglee ® ...

Next, AbbVie argues that biological products are fundamentally different from small molecule drugs because they are more likely to be immunogenic and biosimilars cannot be shown to be the same as ...

Sgt. Zach Smola, rear door gunner on a CH-47, keeps watch on the mountains in Uruzgan province, Afghanistan, May 12, 2013. The Chinooks, operated by members of Bravo Company, 2nd Battalion, 104th ...

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician. An interchangeable designation means that the product, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press ...

President Joe Biden’s budget proposal for fiscal 2025 includes a proposal that would allow pharmacy substitution of biosimilar drugs for the reference product, even if they are not designated as ...

Credit: Getty Images. Rezvoglar may now be substituted for Lantus at the pharmacy counter without the need for an intervention from the prescriber. The Food and Drug Administration (FDA) has approved ...

When US regulators approved a new drug called Zarxio in March, it became the first FDA-approved biosimilar: a "copy" of a medication made from living things. Drugs derived from biological substances ...